A clinical trial with oral leniolisib in patients with APDS as well as with Sjoberg diseases led to improve immune regulation and to a dose-dependent reduction in PI3K/AKT pathway activity [77]. This evidence concerns the gene PIK3CD and activated PI3K-delta syndrome.